Chemed Corp
NYSE:CHE
P/FCFE
Price to FCFE
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | P/FCFE | ||||
---|---|---|---|---|---|
US |
Chemed Corp
NYSE:CHE
|
8.3B USD | 27.8 | ||
US |
Cigna Corp
NYSE:CI
|
94.1B USD | 10.4 | ||
US |
C
|
Cigna Group
XMUN:CGN
|
87.4B EUR | 10.4 | |
US |
CVS Health Corp
NYSE:CVS
|
70.2B USD | 4.7 | ||
DE |
Fresenius SE & Co KGaA
XETRA:FRE
|
16.4B EUR | 6.1 | ||
US |
Laboratory Corporation of America Holdings
NYSE:LH
|
16.3B USD | 59.2 | ||
US |
Quest Diagnostics Inc
NYSE:DGX
|
15.5B USD | 9.8 | ||
US |
DaVita Inc
NYSE:DVA
|
12.9B USD | 9.4 | ||
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.5B EUR | 170.9 | |
DE |
Fresenius Medical Care AG
XMUN:FME
|
11.4B EUR | 170.3 | ||
US |
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | -29 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.